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Amniotic ﬂuid embolism (AFE) is one of the leading causes of maternal mortality and morbidity in developed countries.
Current thinking about pathophysiology has shifted away from embolism toward a maternal immune response to the fetus.
Two immunologic mechanisms have been studied to date. Anaphylaxis appears to be doubtful while the available evidence
supports a role for complement activation. With the mechanism remaining to be elucidated, AFE remains a clinical diagnosis.
It is diagnosed based on one or more of four key signs/symptoms: cardiovascular collapse, respiratory distress, coagulopathy,
and/or coma/seizures. The only laboratory test that reliably supports the diagnosis is the ﬁnding of fetal material in the maternal
pulmonary circulation at autopsy. Perhaps the most compelling mystery surrounding AFE is not why one in 20,000 parturients
are aﬄicted, but rather how the vast majority of women can tolerate the foreign antigenic presence of their fetus both within their
uterus and circulation?
1.Introduction
When ﬁrst described in the ﬁrst half of the 20th century,
amnioticﬂuidembolismwaspresumedtobetheresultofthe
physical obstruction of the maternal pulmonary circulation
by fetal material contained within amniotic ﬂuid [1, 2]. In
the initial cases described at autopsy, abundant fetal material
was seen in pulmonary vessels. The disease is rare, with an
incidence ranging from one in 600 to one in 80,000, perhaps
because there is no established laboratory marker diagnostic
suitable for both survivors and fatalities alike [3, 4]. AFE
is one of the leading causes of maternal mortality in the
United States and causes roughly 10% of all maternal deaths
in developed countries [5–7]. Perhaps an equal concern is
the signiﬁcant maternal morbidity that results in survivors.
In 48 British survivors, four had neurological injury, two had
thrombotic events, one had renal failure, and another had
septicemia [8]. 94% were admitted to the ICU. In an Aus-
tralian study, three of thirteen survivors suﬀered a cerebral
infarction [9]. The morbidity and mortality for the fetus
is also signiﬁcant. In the British registry, among the ﬁfteen
womenwhodiedofAFE,elevenoftheirbabiesdiedalso,and
one of the survivors had hypoxic ischemic encephalopathy
[7]. Among the thirty-one surviving women with known
newborn outcomes, nine newborns died or suﬀered serious
injury. Although a rare complication of pregnancy, the high
rates of injury for both mother and newborn provide com-
pelling arguments for a better understanding of the mecha-
nism of disease.
While “embolism” is contained with the disease name
both in its original Spanish and English descriptions, there
are a number of confounding clinical observations about
AFE that cast doubt on this mechanism of disease [1, 2].
First,mechanicalobstructionofpulmonarybloodﬂowisnot
reliably seen in AFE [10]. Second, clinical events, common
in AFE, coagulopathy, adult respiratory distress syndrome,
and neurological symptoms, are not typical in pulmonary
embolism. Perhaps as a result, observers began speculating
about a possible role for an immune mechanism as early as
1950 [11]. Yet with the disease appearing rarely, suddenly,
and unpredictably, obtaining relevant evidence in humans
has proven unusually diﬃcult. Unfortunately, animal studies
have provided little insight other than to suggest there is little
to learn from animal models. Illness has been induced in
animals (rabbits and dogs) with the intravascular injection
of heterologous (human) amniotic ﬂuid contaminated by2 Clinical and Developmental Immunology
meconium [2]. In particular, autologous amniotic ﬂuid
introduced into the maternal circulation in monkeys seems
to be entirely benign [12, 13].
2. Anaphylaxis
T h eﬁ r s ts p e c i ﬁ cs u g g e s t i o no fa n a p h y l a x i sa sam e c h a n i s m
of AFE was made by Attwood in 1956 [14]. Benson and
Lindburgh suggested that this hypothesis was testable in
humans by testing women acutely ill with AFE for serum
tryptase [15]. Tryptase, a serine protease with a half-life of
several hours, is released by mast cells along with histamine
when they degranulate in response to IgE crosslinking on the
cell surface in the presence of antigen. Although the speciﬁc
function of tryptase in anaphylaxis is unknown, with a half
life measured in hours instead of the minutes of histamine,
the protein has proven useful in the diagnosis of anaphylaxis.
Urinary histamine has also been used to diagnose anaphy-
laxis as a small percentage of histamine is excreted into the
urine, unmetabolized [16].
In considering the role of mast cell degranulation in the
mechanism of amniotic ﬂuid embolism, the serological evi-
dence should be considered separately from the histological
data since, in both cases, the evidence is somewhat mixed.
Serum tryptase testing in AFE points against a role for AFE
while tryptase staining in pulmonary histology at autopsy
provides a more nuanced picture.
In 2001, a study of nine women with amniotic ﬂuid
embolism was published in which speciﬁc evidence of
anaphylaxis was sought [17]. Seven of the nine patients had
sera stored as part of the Japanese National Maternal Mor-
tality Surveillance project while two patients were American
survivors enrolled in a protocol speciﬁcally created to collect
acutesamplesinAFEpatients.Fivepatientswerenegativefor
serum tryptase, one was negative for urinary histamine, and
one was negative for both. There were no positive ﬁndings
for either serum tryptase or urinary histamine in any of the
patients.
Since this study, elevated serum tryptase levels have
been reported in fatal cases of amniotic ﬂuid embolism.
In three such reports, serum tryptase levels have been only
slightly elevated, raising serious questions about the premise
that anaphylaxis reﬂects the underlying mechanism [18–
20]. In the fourth case of AFE, the authors also looked at
postmortem serum tryptase levels in nonpregnant, non-AFE
casessuchaspulmonaryembolismandtraﬃcaccidents[21].
While the serum tryptase level in the AFE case was six times
the upper level of normal, 17 hours after death, the one
conﬁrmed anaphylaxis case had a tryptase levels over 60
times normal, 24 hours after death. Finally tryptase levels
in a ﬁfth, surviving case of AFE were normal [22]. The
slight serum elevations in fatal cases of AFE are below that
normally seen for postmortem values seen in anaphylaxis
and do not support the hypothesis that mast cell degranu-
lation plays a central role in the pathophysiology of amniotic
ﬂuid embolism.
With100%of6AFEpatientstestingnegativefortryptase
in the largest series to date, the best that can be said about
serumtryptaseinAFEisthatithasverypoorsensitivity[17].
However, there are objections to the speciﬁcity of the test as
w e l l .U n l e s st r y p t a s ei sm e a s u r e di nb o t hn o r m a lp a r t u r i e n t s
and mortally ill obstetric patients with illnesses other than
AFE, the speciﬁcity of tryptase will remain unknown. It is
possible that tryptase is elevated in speciﬁc obstetric popu-
lations without AFE. At the present, serum tryptase in AFE
can only be considered an investigational tool with both
normal and elevated levels neither conﬁrming nor excluding
the diagnosis.
The evidence from maternal pulmonary histology is
more complex concerning the role of anaphylaxis in AFE.
Two studies by Italian pathologists did ﬁnd evidence of mast
cell degranulation in the maternal pulmonary vasculature.
T h eﬁ r s ts t u d yp e r f o r m e dm a s tc e l lc o u n t sp e rﬁ x e da r e ab y
using an immunohistochemical stain for tryptase [23]. The
investigators compared the six fatal AFE cases with six ana-
phylactic deaths, ﬁve traumatic pregnancies deaths, and six
traumatic deaths in nonpregnant women. Remarkably, the
AFE group had higher mast cell densities than the anaphy-
lactic group and much higher than the other two control
groups. In the second study using a similar approach, the
investigators were able to show a large increase in extracel-
lular tryptase consistent with mast cell degranulation in the
eight women in the AFE group compared to the six pregnant
women who succumbed from traumatic injury [20]. One
case report of AFE failed to ﬁnd immunohistochemical evi-
denceofmastcelldegranulationatautopsy,butthepatientin
question died minutes after a head on motor vehicle accident
and did not clearly have AFE [24].
Insummary,theavailableevidencesuggeststhatmastcell
degranulation does take place in the lungs in fatal AFE cases
and does not do so in other mortal pregnancy conditions.
This is hard to reconcile with the general lack of signiﬁcant
circulating tryptase elevations in AFE. These observations
together suggest that pulmonary mast cell involvement in
fatal cases may be a secondary process and not necessarily
the primary mechanism of AFE. This possibility is all the
more intriguing because mast cell degranulation can occur
as a result of complement activation [25]. In considering the
mechanism of disease, evidence of tryptase release cannot be
taken as proof as a primary role for anaphylaxis without the
simultaneous measurement of complement and conﬁrming
that activation did not take place.
Finally before leaving the subject of anaphylaxis and
amniotic ﬂuid embolism, the suggestion that the disease be
renamed “Anaphylactoid Syndrome of Pregnancy” should be
considered [26, 27]. While the term “anaphylaxis” can refer
loosely to the clinical symptoms resulting from any process
resulting in mast cell degranulation, it is more commonly
used to denote a process mediated by IgE binding to antigen
[28]. In contrast, the common usage of “anaphylactoid” is
used speciﬁcally to refer to nonimmune-mediated degranu-
lation of mast cells—not involving IgE [29]. The best known
example in humans of an “anaphylactoid” reaction is the
histamine release that is sometimes seen in people with their
ﬁrst exposure to intravenous X-ray contrast [30]. Potentially
asfatalasIgE-mediatedanaphylaxis,thepresumptionunder-
lying anaphylactoid reactions is that they do not result fromClinical and Developmental Immunology 3
a remembered antigenic response since there has not been
previous exposure. Beyond the fact that mast cell degran-
ulation is by no means a proven mechanism of AFE is the
ideathatallspeculationregardingdiseasemechanismcenters
on some type of maternal immune response to fetal antigen
[31]. No mechanism has been proposed for AFE in which
mast cells degranulate in the absence of antibody-antigen
interaction. Although “Anaphylactoid Syndrome of Preg-
nancy” has not gained widespread acceptance, available evi-
dence does not support changing the name of AFE, and the
term should be abandoned.
3.ComplementActivationinAFE
The frequency of adult respiratory distress syndrome as a
sequela of AFE suggested to Jacob and Hammershmidt in
1982 [32], and Hammershmidt et al. [33] that complement
activation may have a role to play in the pathophysiology of
disease. The ﬁrst series in which serum complement levels
were evaluated in AFE patients found that both C3 and
C4 were signiﬁcantly depressed in all eight AFE patients in
which measurements could be done [17]. A control group of
twenty-three normal laboring patients all had complement
levelsinthenormalrange.Furthermore,inacasereportcon-
cerning possible “mild” AFE in which a patient had transient
shortness of breath, palpitations, and laboratory evidence
for a coagulopathy, complement levels were also depressed
[34]. However, in a separate series of AFE patients in Japan,
the average C3 level was low normal (71mg/dL) while the
average C4 levels were depressed (13.9mg/dL) [7]. There
werenodiﬀerencesinthemeansbetweenthosewhosurvived
and those who died. The Italian group that did histology
studiesfortryptasealsoconsideredcomplementactivationin
their most recent paper [20]. They found depressed amounts
ofC3ainthepulmonarycirculationoftheeightAFEpatients
compared to the six pregnant women dying of trauma.
The investigators suggested that the diminished pulmonary
C3a was consistent with complement activation. As noted
previously,therewasevidencefortryptasereleaseinthesame
histology samples. It is possible, if not likely, that comple-
ment activation may have been the initial immune response
which then resulted in a secondary degranulation of mast
cells.
With both serologic and histologic evidence, the comple-
ment pathway appears more promising than anaphylaxis as
a possible mechanism of disease. However, as a diagnostic
tool, both sensitivity and speciﬁcity are poorly characterized.
As with tryptase, complement levels in AFE remain an
investigational tool and should not be used to either conﬁrm
or refute a clinical diagnosis.
During the investigations into complement activation
in AFE, an interesting footnote should be mentioned. It
appears that some degree of complement activation during
normal labor is physiologic and peaks at the moment of
birth. Two separate studies in which serial complement levels
were obtained in normal laboring parturients have been per-
formed. The ﬁrst was done as part of the 2001 study looking
at complement and tryptase levels in AFE [17]. A healthy
control group of thirteen American women and nine
Japanese women had complement levels obtained on admis-
sion to the hospital in labor and on the ﬁrst postpartum
day. A within pairs analysis was performed, and both C3
and C4 demonstrated statistically signiﬁcant declines, 8%
and 5%, respectively. In a second study of twelve healthy
American women, serial complement levels were obtained
several times during labor and within an hour postpartum
[35]. Again, the decreases in complement levels were highly
statistically signiﬁcant with C3 dropping an average of 15%
and C4 diminishing by 11%. In both studies, all complement
levels remained within the normal range. Taken together,
they suggest that complement activation peaks at or shortly
before birth and that levels start to return to normal in the
postpartum period [10]. The biological signiﬁcance of com-
plement activation during normal parturition is unknown
but is consistent with current evidence that the initiation of
labor may be mediated by an inﬂammatory response rather
than simply a ﬂuctuation in hormones [36].
4.ClinicalDiagnosisof AFE
There is a reasonably broad consensus in the published liter-
ature on the clinical diagnosis of AFE without the reliance on
laboratory markers. In general, the deﬁnitions of the disease
point to one or more of the following clinical signs ﬁrst
characterizedbyCourtneyin1974:cardiovascularinstability,
respiratory distress, coagulopathy, or coma/seizures in the
absence of other explanations [37]. Benson used the same
deﬁnition for his research protocols but stipulated a forty-
eight hour time limit from birth [10]. The Japan Consensus
Criteria for the diagnosis of AFE was similar with the
omission of neurological symptoms and a twelve-hour limit
from birth [7]. Conde-Agudelo and Romero of the National
InstitutesofHealthadoptedtheBensondeﬁnitionforclinical
diagnosis in their 2009 review article, which was also used
in an Australian population-based cohort study [9, 38]. In
sum, the clinical deﬁnition of AFE has remained reasonably
constant over the past four decades.
The UK Obstetric Surveillance System criteria for AFE
are a bit more nuanced although still clearly similar to
the Japanese and the American clinical deﬁnitions [39].
The British do not deﬁne a time limit from parturition
and include maternal hemorrhage, in general, as well as
coagulopathy. Unlike the other clinical deﬁnitions, they do
consider acute fetal compromise in the absence of other clear
cause as a diagnostic sign of AFE. They also include nonspe-
ciﬁc premonitory symptoms such as restlessness or numb-
ness, agitation, and tingling. Perhaps most signiﬁcantly, the
British include one laboratory test as being suﬃcient for the
diagnosis regardless of clinical course—the ﬁnding of fetal
material in the maternal pulmonary vasculature at autopsy.
There are several nuances to the clinical diagnosis of
AFE. All deﬁnitions assign the diagnosis with the proviso
that alternative diagnoses have been excluded although this
does not preclude other comorbidities such as abruption. Yet
several other clinical ﬁndings are associated with AFE even if
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For instance, uterine atony has been closely associated with
AFE in several reports [37, 40]. Beyond being a diagnostic
criteria in the United Kingdom, several case reports have also
described fetal bradycardia occurring early in the onset of
amnioticﬂuidembolism [6,41,42].Regardingcoagulopathy
and the diagnosis of amniotic ﬂuid embolism, at least six
case reports have described coagulopathy alone as the sole
clinical sign/symptom of AFE [43–48]. It should also be
noted that all clinical deﬁnitions of the disease described
above anticipate that coagulopathy occurring in isolation
may be the sole clinical sign/symptom of AFE [7, 10, 37–39].
5.LaboratoryDiagnosisofAFE
An examination of the current state of laboratory diagnosis
of AFE is fraught with conﬂicting and paradoxical evidence.
To be sure, AFE as a clinical entity emerged from the autopsy
roomwitheightmaternaldeathsattheUniversityofChicago
deﬁning the ﬁrst series of the disease. These ﬁrst cases had
large amounts of apparent fetal material in the maternal
pulmonary vasculature. It is, therefore, no surprise that
ﬁnding any fetal material in the maternal circulation has
been presumed to conﬁrm a diagnosis of AFE. However, this
is clearly not the case as there have been any number of
both individual case reports and case series in which fetal
material is present in the maternal circulation in women not
experiencing AFE. To add confusion to the issue, the limited
autopsy studies available draw quite a diﬀerent picture from
studies in living patients.
There are a growing number of reports in the literature
in which fetal material is found in the maternal circulation of
living parturients who do not have amniotic ﬂuid embolism.
Perhaps the earliest reports are those of two separate cases in
which fetal material was found in the maternal circulation
of the uterus at the time of peripartum hysterectomy in
women who did not have AFE [49, 50]. In the 1980s, at least
three studies were done in which pulmonary artery samples
were taken from critically ill pregnant patients, looking for
fetal material [51–53]. Any number of these aspirates had
fetal material, ranging from squamous to mucin to lanugo
in women who did not have AFE. This is further supported
by a recent pathology study of 57 peripartum hysterectomy
specimens for women who were experiencing excessive
bleeding [54]. There was no relationship between the pres-
ence or absence of uterine intravascular fetal material and
the etiology of maternal hemorrhage. Seven diagnoses were
attributedtotheetiologyofthehemorrhage:uterinerupture,
abruption, uterine atony, placenta previa, accreta, coagu-
lopathy, and retained placenta. Speciﬁcally, women in all
seven diagnostic categories had both the presence and the
absence of fetal material including those with disseminated
intravascularcoagulopathy,oneofthesignsofamniotic ﬂuid
embolism.
In contrast, two case reports relied on the observation
of intravascular fetal material in the uterus to conﬁrm a
diagnosisofamnioticﬂuidembolism.Intheﬁrst,theauthors
assume that they “prevented AFE” by ligating the uterine
vessels with the fetal material in it [55]. They saw vernix
and air bubbles entering the uterine vein and ligated the
uterine vessels without removing the uterus. The patient’s
only morbidity was a subclinical laboratory coagulopathy. In
the second case report, the authors similarly assume that a
fatal case was averted because the fetal material did not enter
the pulmonary circulation [43]. They observed fetal material
within the uterine veins after a peripartum hysterectomy
on histology studies. In light of the numerous reports cited
previously, the currently available evidence does not support
using the presence or absence of intravascular fetal materials
in living patients to conﬁrm or refute a diagnosis of AFE.
To make matters more confusing, the limited data from
autopsy studies suggest that intravascular fetal material
is both sensitive and speciﬁc for AFE. In 1998, Japanese
investigators used a immunohistochemical stain for a fetal
antigen, STN, to make a diagnosis of AFE at autopsy [56]. All
four AFE patients had positive staining of the pulmonary
vasculature while the control group of four women who died
from non-AFE causes did not. A second study of twenty-
seven maternal deaths found fetal material in 100% of AFE
patients and none in those dying of non-AFE causes [57].
It should be noted that the study ﬁndings were problematic
since the authors began with the assumption that any fetal
material in the maternal vasculature was diagnostic of AFE.
With that said, they did not ﬁnd fetal material in any cases
that were obviously not AFE such as traumatic injury. The
previouslycitedItalianstudiesalsofoundfetalmaterialinthe
pulmonary vasculature in AFE patients at autopsy while not
ﬁnding it in pregnant women dying of other causes [20, 23].
The evidence from several dozen autopsies on women with
and without AFE suggests that the ﬁnding of fetal material
in the maternal circulation at autopsy is speciﬁc for AFE.
This fact is utilized in the diagnostic criteria of the United
Kingdom as the only laboratory test considered diagnostic
[39]. Similarly, histology at autopsy seems to be sensitive for
AFE although, in all studies, specialized stains were used to
look for fetal material.
The diﬀerence in the presence of fetal material in the
maternal vasculature between those dying and surviving is
seen in another study of 135 women with AFE in Japan [7].
In this study, serum levels of a speciﬁc fetal antigen, STN,
were higher in those succumbing to the disease. However,
the levels between survivors and those dying did overlap
suﬃciently to prevent STN levels alone from being a very
useful, discriminating diagnostic marker for AFE.
As with tryptase and complement, the presence or the
absence of fetal material in the maternal circulation of living
women cannot either conﬁrm or refute the diagnosis of AFE.
However, the limited available evidence suggests a somewhat
diﬀerent conclusion at autopsy, where the presence of
intravascular fetal material does seem to be speciﬁc for AFE.
Itisunclearwhythereshouldbeadiﬀerenceinthesensitivity
and speciﬁcity of intravascular fetal material between the
living and the dead. An obvious explanation is that a greater
amount of fetal material may be more mortal and thus
more detectable at autopsy. Yet this does not seem entirely
satisfactory on further examination since the amount of fetal
material in fatal AFE cases was not necessarily massive and
indeed present only in microscopic amounts.Clinical and Developmental Immunology 5
6. Conclusions
Much has been published about amniotic ﬂuid embolism
that, in light of current evidence, needs to be revised. The
evidence does not support renaming the disease “Anaphy-
lactoid Syndrome of Pregnancy.” The only laboratory test
that is diagnostic at this time is the ﬁnding of fetal material
in the maternal pulmonary circulation at autopsy. Serum
tryptase levels should not be used to aﬃrm or refute a
diagnosis of AFE. Similarly, while there is better evidence
concerning complement, it too remains an investigational
tool and is not yet a reliable diagnostic marker. There is
enough of a worldwide consensus on diagnostic criteria
to permit reasonably consistent clinical diagnoses in the
absence of conﬁrmatory laboratory testing at the present.
Generally,thediagnosisreliesononeormoreoffoursignsor
symptoms occurring during pregnancy or shortly thereafter:
cardiovascular collapse, respiratory distress, coagulopathy,
and coma or seizures. Finally, intravascular fetal material
in living women clearly does not necessarily result in AFE
although it may not be either benign or physiologic. Perhaps
the best way forward is the continued use of a diﬃcult but
achievable methodology—looking at immune markers in
sera obtained from healthy controls and acutely ill pregnant
women, both with and without AFE. The study of AFE is
important both because it causes signiﬁcant morbidity and
mortality among mothers and their babies and also because
a better understanding of this disease may lead to a more
insight into immune tolerance in general. The overarching
importance of the question underlying the mechanism of
AFE is not so much why does a speciﬁc patient get the
disease but rather how can women tolerate the presence of
so much foreign antigen within both their uterus and their
circulation?
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